Vol. 2 No. 6 (2022): June
Health Technology Reviews

Ibrutinib for Chronic Graft-Versus-Host Disease

Published June 22, 2022

Key Messages

  • No eligible evidence was identified comparing ibrutinib to another intervention for the management of treatment-refractory chronic graft-versus-host disease.
  • Currently available evidence describing second- or third-line therapies for treatment-refractory chronic graft-versus-host disease was ineligible for this review because of the use of non-comparative research methods (i.e., single-arm trials, case series, and case reports).
  • One randomized controlled trial is currently under way investigating the use of ibrutinib as first-line therapy for chronic graft-versus-host disease; however, no randomized controlled trials of ibrutinib for the management of treatment-refractory chronic graft-versus-host disease are currently being conducted.
  • The need for high-quality randomized controlled trials of ibrutinib for treatment-refractory chronic graft-versus-host disease has been highlighted repeatedly in recent literature.